---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000091"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:00:43.235250+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion prices $200M public offering of 30.8M shares at $6.50 per share

## Summary
- Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
- Offering comprises 30,769,230 shares of Class A common stock at $6.50 per share.
- Underwriters granted 30-day option to purchase up to additional 4,615,384 shares.
- Expected closing date June 28, 2024, subject to customary conditions.
- Goldman Sachs & Co. LLC and J.P. Morgan are lead book-running managers.

## SEC filing metadata
- accession: 0001601830-24-000091
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000091/0001601830-24-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000091/rxrx-20240626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000091
- JSON: https://secwatch.observer/filing/0001601830-24-000091.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.